During the COVID-19 pandemic 20 000 prostate cancer diagnoses were missed in England
© 2024 The Authors. BJU International published by John Wiley & Sons Ltd on behalf of BJU International..
OBJECTIVES: To investigate the effect of the COVID-19 pandemic on prostate cancer incidence, prevalence, and mortality in England.
PATIENTS AND METHODS: With the approval of NHS England and using the OpenSAFELY-TPP dataset of 24 million patients, we undertook a cohort study of men diagnosed with prostate cancer. We visualised monthly rates in prostate cancer incidence, prevalence, and mortality per 100 000 adult men from January 2015 to July 2023. To assess the effect of the pandemic, we used generalised linear models and the pre-pandemic data to predict the expected rates from March 2020 as if the pandemic had not occurred. The 95% confidence intervals (CIs) of the predicted values were used to estimate the significance of the difference between the predicted and observed rates.
RESULTS: In 2020, there was a drop in recorded incidence by 4772 (31%) cases (15 550 vs 20 322; 95% CI 19 241-21 403). In 2021, the incidence started to recover, and the drop was 3148 cases (18%, 17 950 vs 21 098; 95% CI 19 740-22 456). By 2022, the incidence returned to the levels that would be expected. During the pandemic, the age at diagnosis shifted towards older men. In 2020, the average age was 71.6 (95% CI 71.5-71.8) years, in 2021 it was 71.8 (95% CI 71.7-72.0) years as compared to 71.3 (95% CI 71.1-71.4) years in 2019.
CONCLUSIONS: Given that our dataset represents 40% of the population, we estimate that proportionally the pandemic led to 20 000 missed prostate cancer diagnoses in England alone. The increase in incidence recorded in 2023 was not enough to account for the missed cases. The prevalence of prostate cancer remained lower throughout the pandemic than expected. As the recovery efforts continue, healthcare should focus on finding the men who were affected. The research should focus on investigating the potential harms to men diagnosed at older age.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:133 |
|---|---|
| Enthalten in: |
BJU international - 133(2024), 5 vom: 27. Apr., Seite 587-595 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lemanska, Agnieszka [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID‐19 |
|---|
| Anmerkungen: |
Date Completed 23.04.2024 Date Revised 24.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/bju.16305 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369041488 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369041488 | ||
| 003 | DE-627 | ||
| 005 | 20240424232011.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240229s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/bju.16305 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1385.xml |
| 035 | |a (DE-627)NLM369041488 | ||
| 035 | |a (NLM)38414224 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lemanska, Agnieszka |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a During the COVID-19 pandemic 20 000 prostate cancer diagnoses were missed in England |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.04.2024 | ||
| 500 | |a Date Revised 24.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024 The Authors. BJU International published by John Wiley & Sons Ltd on behalf of BJU International. | ||
| 520 | |a OBJECTIVES: To investigate the effect of the COVID-19 pandemic on prostate cancer incidence, prevalence, and mortality in England | ||
| 520 | |a PATIENTS AND METHODS: With the approval of NHS England and using the OpenSAFELY-TPP dataset of 24 million patients, we undertook a cohort study of men diagnosed with prostate cancer. We visualised monthly rates in prostate cancer incidence, prevalence, and mortality per 100 000 adult men from January 2015 to July 2023. To assess the effect of the pandemic, we used generalised linear models and the pre-pandemic data to predict the expected rates from March 2020 as if the pandemic had not occurred. The 95% confidence intervals (CIs) of the predicted values were used to estimate the significance of the difference between the predicted and observed rates | ||
| 520 | |a RESULTS: In 2020, there was a drop in recorded incidence by 4772 (31%) cases (15 550 vs 20 322; 95% CI 19 241-21 403). In 2021, the incidence started to recover, and the drop was 3148 cases (18%, 17 950 vs 21 098; 95% CI 19 740-22 456). By 2022, the incidence returned to the levels that would be expected. During the pandemic, the age at diagnosis shifted towards older men. In 2020, the average age was 71.6 (95% CI 71.5-71.8) years, in 2021 it was 71.8 (95% CI 71.7-72.0) years as compared to 71.3 (95% CI 71.1-71.4) years in 2019 | ||
| 520 | |a CONCLUSIONS: Given that our dataset represents 40% of the population, we estimate that proportionally the pandemic led to 20 000 missed prostate cancer diagnoses in England alone. The increase in incidence recorded in 2023 was not enough to account for the missed cases. The prevalence of prostate cancer remained lower throughout the pandemic than expected. As the recovery efforts continue, healthcare should focus on finding the men who were affected. The research should focus on investigating the potential harms to men diagnosed at older age | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a COVID‐19 | |
| 650 | 4 | |a missed diagnosis | |
| 650 | 4 | |a prostate cancer cohort | |
| 650 | 4 | |a prostate cancer diagnosis | |
| 650 | 4 | |a prostate cancer incidence | |
| 650 | 4 | |a prostate cancer prevalence | |
| 700 | 1 | |a Andrews, Colm |e verfasserin |4 aut | |
| 700 | 1 | |a Fisher, Louis |e verfasserin |4 aut | |
| 700 | 1 | |a Bacon, Seb |e verfasserin |4 aut | |
| 700 | 1 | |a Mehrkar, Amir |e verfasserin |4 aut | |
| 700 | 1 | |a Inglesby, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Davy, Simon |e verfasserin |4 aut | |
| 700 | 1 | |a Goldacre, Ben |e verfasserin |4 aut | |
| 700 | 1 | |a MacKenna, Brian |e verfasserin |4 aut | |
| 700 | 0 | |a OpenSAFELY Collaborative |e verfasserin |4 aut | |
| 700 | 1 | |a Walker, Alex J |e verfasserin |4 aut | |
| 700 | 1 | |a Rentsch, Christopher T |e investigator |4 oth | |
| 700 | 1 | |a Curtis, Helen J |e investigator |4 oth | |
| 700 | 1 | |a Morton, Caroline E |e investigator |4 oth | |
| 700 | 1 | |a Morley, Jessica |e investigator |4 oth | |
| 700 | 1 | |a Hickman, George |e investigator |4 oth | |
| 700 | 1 | |a Bates, Chris |e investigator |4 oth | |
| 700 | 1 | |a Croker, Richard |e investigator |4 oth | |
| 700 | 1 | |a Evans, David |e investigator |4 oth | |
| 700 | 1 | |a Ward, Tom |e investigator |4 oth | |
| 700 | 1 | |a Cockburn, Jonathan |e investigator |4 oth | |
| 700 | 1 | |a Bhaskaran, Krishnan |e investigator |4 oth | |
| 700 | 1 | |a Schultze, Anna |e investigator |4 oth | |
| 700 | 1 | |a Williamson, Elizabeth J |e investigator |4 oth | |
| 700 | 1 | |a Hulme, William J |e investigator |4 oth | |
| 700 | 1 | |a McDonald, Helen I |e investigator |4 oth | |
| 700 | 1 | |a Tomlinson, Laurie |e investigator |4 oth | |
| 700 | 1 | |a Mathur, Rohini |e investigator |4 oth | |
| 700 | 1 | |a Eggo, Rosalind M |e investigator |4 oth | |
| 700 | 1 | |a Wing, Kevin |e investigator |4 oth | |
| 700 | 1 | |a Wong, Angel Y S |e investigator |4 oth | |
| 700 | 1 | |a Forbes, Harriet |e investigator |4 oth | |
| 700 | 1 | |a Tazare, John |e investigator |4 oth | |
| 700 | 1 | |a Parry, John |e investigator |4 oth | |
| 700 | 1 | |a Hester, Frank |e investigator |4 oth | |
| 700 | 1 | |a Harper, Sam |e investigator |4 oth | |
| 700 | 1 | |a Douglas, Ian J |e investigator |4 oth | |
| 700 | 1 | |a Evans, Stephen J W |e investigator |4 oth | |
| 700 | 1 | |a Smeeth, Liam |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t BJU international |d 1999 |g 133(2024), 5 vom: 27. Apr., Seite 587-595 |w (DE-627)NLM101433530 |x 1464-410X |7 nnns |
| 773 | 1 | 8 | |g volume:133 |g year:2024 |g number:5 |g day:27 |g month:04 |g pages:587-595 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/bju.16305 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 133 |j 2024 |e 5 |b 27 |c 04 |h 587-595 | ||